Endoscopic Retrograde Cholangiopancreatography Market Report: Trends, Forecast and Competitive Analysis to 2030

Endoscopic Retrograde Cholangiopancreatography Market Report: Trends, Forecast and Competitive Analysis to 2030

Endoscopic Retrograde Cholangiopancreatography Trends and Forecast

The future of the global endoscopic retrograde cholangiopancreatography market looks promising with opportunities in the hospital and ambulatory surgery center & clinic markets. The global endoscopic retrograde cholangiopancreatography market is expected to reach an estimated $1.9 billion by 2030 with a CAGR of 5.5% from 2024 to 2030. The major drivers for this market are elevated cancer rates, increasing inclination towards minimally invasive procedures and surgeries, and growing financial commitments from governments and healthcare institutions.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Endoscopic Retrograde Cholangiopancreatography by Segment

The study includes a forecast for the global endoscopic retrograde cholangiopancreatography by product, procedure, end use, and region.

Endoscopic Retrograde Cholangiopancreatography Market by Product [Shipment Analysis by Value from 2018 to 2030]:

• Endoscopes
• Endotherapy Devices
• Visualization Systems
• Energy Devices
• Others

Endoscopic Retrograde Cholangiopancreatography Market by Procedure [Shipment Analysis by Value from 2018 to 2030]:

• Biliary Sphincterotomy
• Biliary Stenting
• Biliary Dialtation
• Pancreatic Sphincterotomy
• Pancreatic Duct Stenting
• Pancreatic Duct Dilatation

Endoscopic Retrograde Cholangiopancreatography Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

• Hospitals
• Ambulatory Surgery Centers & Clinics
• Other

Endoscopic Retrograde Cholangiopancreatography Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Endoscopic Retrograde Cholangiopancreatography Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies endoscopic retrograde cholangiopancreatography companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the endoscopic retrograde cholangiopancreatography companies profiled in this report include-

• Hobbs Medical
• STERIS
• Merit Medical Systems
• TeleMed Systems
• Changzhou Health Microport Medical Device

Endoscopic Retrograde Cholangiopancreatography Market Insights

Lucintel forecasts that endotherapy device will remain the largest segment over the forecast period due to growing incidence of gastrointestinal disorders.

Within this market, hospital will remain the largest segment due to availability of wide range of ERCP devices in these facilities.

North America will remain the largest region over the forecast period due to rising frequency of cancer cases and introduction of advanced ERCP tools in the region.

Features of the Global Endoscopic Retrograde Cholangiopancreatography Market

Market Size Estimates: Endoscopic retrograde cholangiopancreatography market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Endoscopic retrograde cholangiopancreatography market size by product, procedure, end use, and region in terms of value ($B).

Regional Analysis: Endoscopic retrograde cholangiopancreatography market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different products, procedures, end uses, and regions for the endoscopic retrograde cholangiopancreatography market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the endoscopic retrograde cholangiopancreatography market.

Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

FAQ

Q1. What is the endoscopic retrograde cholangiopancreatography market size?

Answer: The global endoscopic retrograde cholangiopancreatography market is expected to reach an estimated $1.9 billion by 2030.

Q2. What is the growth forecast for endoscopic retrograde cholangiopancreatography market?

Answer: The global endoscopic retrograde cholangiopancreatography market is expected to grow with a CAGR of 5.5% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the endoscopic retrograde cholangiopancreatography market?

Answer: The major drivers for this market are elevated cancer rates, increasing inclination towards minimally invasive procedures and surgeries, and growing financial commitments from governments and healthcare institutions.

Q4. What are the major segments for endoscopic retrograde cholangiopancreatography market?

Answer: The future of the endoscopic retrograde cholangiopancreatography market looks promising with opportunities in the hospital and ambulatory surgery center & clinic markets.

Q5. Who are the key endoscopic retrograde cholangiopancreatography market companies?

Answer: Some of the key endoscopic retrograde cholangiopancreatography companies are as follows:

• Hobbs Medical
• STERIS
• Merit Medical Systems
• TeleMed Systems
• Changzhou Health Microport Medical Device

Q6. Which endoscopic retrograde cholangiopancreatography market segment will be the largest in future?

Answer: Lucintel forecasts that endotherapy device will remain the largest segment over the forecast period due to growing incidence of gastrointestinal disorders.

Q7. In endoscopic retrograde cholangiopancreatography market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to rising frequency of cancer cases and introduction of advanced ERCP tools in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the endoscopic retrograde cholangiopancreatography market by product (endoscopes, endotherapy devices, visualization systems, energy devices, and others), procedure (biliary sphincterotomy, biliary stenting, biliary dialtation, pancreatic sphincterotomy, pancreatic duct stenting, and pancreatic duct dilatation), end use (hospitals, ambulatory surgery centers & clinics, and other), and region (North America, Europe, Asia Pacific, and the Rest of the World)?

Q.2. Which segments will grow at a faster pace and why?

Q.3. Which region will grow at a faster pace and why?

Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?

Q.5. What are the business risks and competitive threats in this market?

Q.6. What are the emerging trends in this market and the reasons behind them?

Q.7. What are some of the changing demands of customers in the market?

Q.8. What are the new developments in the market? Which companies are leading these developments?

Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?

Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?

Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Please note: It will take 3 business days to deliver the report upon receipt the order.